Type 2 diabetes mellitus is associated with the fibrosis severity in patients with nonalcoholic fatty liver disease in a large retrospective cohort of Japanese patients

Journal of Gastroenterology

Volumn 49, Issue 11, 2014, Pages 1477-1484

  Nakahara, Takashi ^a   Hyogo, Hideyuki ^a   Yoneda, Masato ^b,c   Sumida, Yoshio ^d   Eguchi, Yuichiro ^e   Fujii, Hideki ^f   Ono, Masafumi ^g   Kawaguchi, Takumi ^h   Imajo, Kento ^b   Aikata, Hiroshi ^a   Tanaka, Saiyu ⁱ   Kanemasa, Kazuyuki ⁱ   Fujimoto, Kazuma ^e   Anzai, Keizo ^e   Saibara, Toshiji ^g   Sata, Michio ^h   Nakajima, Atushi ^b   Itoh, Yoshito ^d   Chayama, Kazuaki ^a   Okanoue, Takeshi ^j  

^a HIROSHIMA UNIVERSITY   (Japan)

^b YOKOHAMA CITY UNIVERSITY   (Japan)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^d KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^e SAGA UNIVERSITY   (Japan)

^f OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^g KOCHI MEDICAL SCHOOL   (Japan)

^h KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

ⁱ Nara City Hospital   (Japan)

^j Saiseikai Imperial Gift Foundation Inc Saiseikai Suita Hospital   (Japan)

more..

Author keywords

Diabetes mellitus; Histology; NAFLD; Retrospective study

Indexed keywords

GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; BLOOD GLUCOSE MONITORING; BODY MASS; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; DYSLIPIDEMIA; FEMALE; GLUCOSE BLOOD LEVEL; GROUPS BY AGE; HUMAN; HUMAN TISSUE; HYPERTENSION; HYPERTRIGLYCERIDEMIA; JAPANESE (PEOPLE); LIFESTYLE; LIVER BIOPSY; LIVER FIBROSIS; LIVER HISTOLOGY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; POSTMENOPAUSE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TRIACYLGLYCEROL BLOOD LEVEL; AGE; ASIAN CONTINENTAL ANCESTRY GROUP; BIOPSY; CLINICAL TRIAL; COMPLICATION; DIABETES MELLITUS, TYPE 2; DYSLIPIDEMIAS; ETHNOLOGY; JAPAN; LIVER; LIVER CIRRHOSIS; MIDDLE AGED; OBESITY; PATHOLOGY; PREVALENCE; RISK FACTOR; SEVERITY OF ILLNESS INDEX; STATISTICAL MODEL;

ADULT; AGE FACTORS; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; BIOPSY; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; DYSLIPIDEMIAS; FEMALE; HUMANS; HYPERTENSION; JAPAN; LIVER; LIVER CIRRHOSIS; LOGISTIC MODELS; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; OBESITY; PREVALENCE; RETROSPECTIVE STUDIES; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 84926643436     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-013-0911-1     Document Type: Article

References (45)

1. Hamaguchi M, Kojima T, Takeda N, Nakagawa T, Taniguchi H, Fujii K, et al. The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Int Med. 2005;143:722-8.
2. Kojima S, Watanabe N, Numata M, Ogawa T, Matsuzaki S. Increase in the prevalence of fatty liver in Japan over the past 12 years: analysis of clinical background. J Gastroenterol. 2003;38:954-61.
3. Amarapurkar DN, Hashimoto E, Lesmana LA, Sollano JD, Chen PJ, Goh KL, Asia-Pacific Working Party on NAFLD. How common is non-alcoholic fatty liver disease in the Asia-Pacific region and are there local differences? J Gastroenterol Hepatol. 2007;22:788-93.
4. Teli MR, James OF, Burt AD, Bennett MK, Day CP. The natural history of nonalcoholic fatty liver: a follow-up study. Hepatology. 1995;22:1714-9.
5. Tokushige K, Hashimoto E, Horie Y, Taniai M, Higuchi S. Hepatocellular carcinoma in Japanese patients with nonalcoholic fatty liver disease, alcoholic liver disease, and chronic liver disease of unknown etiology: report of the nationwide survey. J Gastroenterol. 2011;46:1230-7.
6. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: spectrum of clinical and pathological severity. Gastroenterology. 1999;116: 1413-9.
7. James O, Day C. Non-alcoholic steatohepatitis: another disease of affluence. Lancet. 1999;353:1634-6.
8. Ono M, Saibara T. Clinical features of nonalcoholic steatohepatitis in Japan: evidence from the literature. J Gastroenterol. 2006;41:725-32.
9. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Bugianesi E, Lenzi M, et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes. 2001;50:1844-50.
10. Hui JM, Farrell GC. Clear messages from sonographic shadows? Links between metabolic disorders and liver disease, and what to do about them. J Gastroenterol Hepatol. 2003;18:1115-7.
11. Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology. 2003;37:917-23.
12. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med. 2002;346:1221-31.
13. Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology. 2006;43:S99-112.
14. Angulo P. Obesity and nonalcoholic fatty liver disease. Nutr Rev. 2007;65:S57-63.
15. Neuschwander-Tetri BA, Clark JM, Bass NM, Van Natta ML, Unalp-Arida A, Tonascia J, et al. Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease. Hepatology. 2010;52:913-24.
16. Larter CZ, Chitturi S, Heydet D, Farrell GC. A fresh look at NASH pathogenesis. Part 1: the metabolic movers. J Gastroenterol Hepatol. 2010;25:672-90.
17. Fracanzani AL, Valenti L, Bugianesi E, Andreoletti M, Colli A, Vanni E, et al. Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes. Hepatology. 2008;48:792-8.
18. Rafiq N, Bai C, Fang Y, Srishord M, McCullough A, Gramlich T, et al. Long-term follow-up of patients with nonalcoholic fatty liver. Clin Gastroenterol Hepatol. 2009;7:234-8.
19. Hossain N, Afendy A, Stepanova M, Nader F, Srishord M, Rafiq N, et al. Independent predictors of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2009;7:1224-9.
20. Yoneda M, Fujii H, Sumida Y, Hyogo H, Itoh Y, Ono M, et al. Platelet count for predicting fibrosis in nonalcoholic fatty liver disease. J Gastroenterol. 2011;46:1300-6.
21. Sumida Y, Yoneda M, Hyogo H, Yamaguchi K, Ono M, Fujii H, et al. A simple clinical scoring system using ferritin, fasting insulin and type IV collagen 7S for predicting steatohepatitis in nonalcoholic fatty liver disease. J Gastroenterol. 2011;46:257-68.
22. The World Medical Association, Inc. Declaration of Helsinki; Ethical principle for medical research involving human subject. Seoul: WMA General Assembly; 2008.
23. Iwamoto K, Kanno K, Hyogo H, Yamagishi S, Takeuchi M, Tazuma S, et al. Advanced glycation end products enhance the proliferation and activation of hepatic stellate cells. J Gastroenterol. 2008;43:298-304.
24. Hyogo H, Tazuma S, Arihiro K, Iwamoto K, Nabeshima Y, Inoue M, et al. Efficacy of atorvastatin for the treatment of nonalcoholic steatohepatitis with dyslipidemia. Metabolism. 2008;57:1711-8.
25. Matsuzawa U, Inoue S, Ikeda Y, Sakata T, Saito Y, Sato Y, Japanese Society for the Study of Obesity, et al. New criteria of obesity (in Japanese). J Jpn Soc Study Obes. 2000;6:18-28.
26. Ricci C, Longo R, Gioulis E, Bosco M, Pollesello P, Masutti F, et al. Noninvasive in vivo quantitative assessment of fat content in human liver. Noninvasive in vivo quantitative assessment of fat content in human liver. J Hepatol. 1997;27:108-13.
27. World Health Organization. Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia: report of a WHO/IDF consultation. Geneva: World Health Organization; 2006.
28. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412-9.
29. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol. 1999;94:2467-74.
30. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41:1313-21.
31. Paul Angulo. Nonalcoholic fatty liver disease. N Engl J Med. 2002;18:1221-31.
32. Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc. 1980;55:434-8.
33. Liou I, Kowdley KV. Natural history of nonalcoholic steatohepatitis. J Clin Gastroenterol. 2006;40(Suppl 1):S11-6.
34. Abdelmalek MF, Diehl AM. Nonalcoholic fatty liver disease as a complication of insulin resistance. Med Clin North Am. 2007;91:1125-49.
35. Kamada Y, Kiso S, Yoshida Y, Chatani N, Kizu T, Hamano M, et al. Estrogen deficiency worsens steatohepatitis in mice fed high-fat and high-cholesterol diet. Am J Physiol Gastrointest Liver Physiol. 2011;301:1031-43.
36. Zhu L, Brown WC, Cai Q, Krust A, Chambon P, McGuinness OP, et al. Estrogen treatment after ovariectomy protects against fatty liver and may improve pathway-selective insulin resistance. Diabetes. 2013;62:424-34.
37. Eguchi Y, Hyogo H, Ono M, Mizuta T, Ono N, Fujimoto K, et al. Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2009 to 2010 in Japan: a multicenter large retrospective study. J Gastroenterol. 2012;47:586-95.
38. Harrison SA, Oliver D, Arnold HL, Gogia S, Neuschwander-Tetri BA. Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. Gut. 2008;57:1441-7.
39. Donati G, Stagni B, Piscaglia F, Venturoli N, Morselli-Labate AM, Rasciti L, et al. Increased prevalence of fatty liver in arterial hypertensive patients with normal liver enzymes: role of insulin resistance. Gut. 2004;53:1020-3.
40. Schrier RW, Arroyo V, Bernardi M, Epstein M, Henriksen JH, Rodés J. Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology. 1988;8:1151-7.
41. Vallance P, Moncada S. Hyperdynamic circulation in cirrhosis: a role for nitric oxide? Lancet. 1991;337:776-8.
42. Paradis V, Perlemuter G, Bonvoust F, Dargere D, Parfait B, Vidaud M, et al. High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: a potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis. Hepatology. 2001;34:738-44.
43. Megyesi C, Samols E, Marks V. Glucose tolerance and diabetes in chronic liver disease. Lancet. 1967;18:1051-6.
44. Petrides AS, DeFronzo RA. Glucose and insulin metabolism in cirrhosis. J Hepatol. 1989;8:107-14.
45. Arase Y, Kobayashi M, Suzuki F, Suzuki Y, Kawamura Y, Akuta N, et al. Effect of type 2 diabetes on risk for malignancies includes hepatocellular carcinoma in chronic hepatitis C. Hepatology. 2013;57:964-73.